Subscribe to Newsletter

Business & Regulation

Business & Regulation Business Practice

Mega-Merger Not To Be

| James Strachan

A newly introduced tax law in the US puts an end to the would-be mega-merger between Pfizer and Allergan

Business & Regulation Business Practice

A Battle of the Sexes

The Power List is back, but is it a fair representation of the male to female ratio in our industry?

Business & Regulation Standards & Regulation

A New Administration

Despite controversies, Robert Califf will finally take the reins at the FDA.

Business & Regulation Business Practice

Pharma Thieves

A new study estimates that 11.6 billion euros’ worth of goods are being stolen across Europe each year – but what about pharmaceuticals?

Business & Regulation Business Practice

Open or Closed Innovation

| Stephanie Vine

Collaboration can be the key to success, but does open innovation truly unlock the right doors?

Business & Regulation Business Practice

Deep Data Diver

Sitting Down With... Brian Overstreet, President at Advera Health Analytics, USA.

Business & Regulation Business Practice

Hail the Tattletale

Does incentivizing informants deter off-label drug marketing ? Should other countries follow suit?

Business & Regulation Formulation

Lean, Mean Stability Machine

The stability of drug formulations is essential. But what should be monitored – and how often?

Business & Regulation Standards & Regulation

Therapeutic Orphans

Neonates have been underserved, potentially missing out on life-giving scientific advances.

Business & Regulation Business Practice

Distraction Tactics

Documents reveal that Turing and Valeant both used PR to divert attention from drug price hikes

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register